HDAC6 and central nervous system cancer: In this context, HDAC6 pharmacological inhibition has been shown to decrease cell proliferation and migration in glioma cells, reduce the activity of glioma stem cells and reduce the growth of both TMZ-sensitive and TMZ-resistant cells in vivo [22].